2014-2019年欧洲药物急诊网络+(Euro-DEN Plus)急诊科就诊的新型精神活性物质相关病例
该研究基于欧洲药物急诊网络(Euro-DEN)Plus数据库,纳入2014年1月至2019年12月24个欧洲国家36个急诊科的43,633例急性娱乐性药物中毒就诊,其中3304例(7.6%)涉及至少一种新型精神活性物质(NPS)。NPS相关就诊以年轻男性为主,2015年达峰(11.9%),2014年以卡西酮为主(78.4%),2019年以合成大麻素为主(72.2%)。NPS相关患者自行离院比例更高(22.8% vs 15.1%),入住重症监护比例更低(3.6% vs 6.1%),住院时间更长(中位5.1小时 vs 4.7小时,p<0.001),死亡率0.5%。
要点
- 43,633例急诊中毒就诊中3304例(7.6%)涉及至少一种NPS,仅17.9%经分析确认。
- NPS相关就诊比例各中心差异大(0-48.8%),有全年数据的中心2015年达峰(11.9%)。
- NPS种类随时间变化:2014年卡西酮占78.4%、合成大麻素占3.4%;2019年卡西酮降至11.6%、合成大麻素升至72.2%。
- NPS相关患者更年轻(中位30岁 vs 32岁,p<0.001)、男性更多(84.8% vs 75.8%,p<0.001)。
- NPS相关患者自行离院更多(22.8% vs 15.1%),入住重症监护更少(3.6% vs 6.1%),住院时间更长(中位5.1小时 vs 4.7小时,p<0.001),死亡率0.5%。
适用人群与场景
- 2014年1月至2019年12月期间,24个欧洲国家36个急诊科就诊的急性娱乐性药物中毒患者。
研究设计与关键结果
- 研究类型为多中心队列研究,数据来自Euro-DEN Plus数据库,共纳入43,633例急诊就诊,其中3304例(7.6%)涉及至少一种NPS。
- NPS相关就诊的病原体识别主要基于自我报告或临床表现,仅17.9%的NPS就诊进行了分析确认。
- NPS相关就诊比例各中心差异大(0-48.8%);有全年数据的中心NPS相关就诊在2015年达峰(11.9%)。
- 2014年NPS中卡西酮占78.4%,合成大麻素占3.4%;2019年卡西酮占11.6%,合成大麻素占72.2%。
- 与其余队列相比,NPS相关患者更年轻(中位30岁(23-37)vs 32岁(25-40),p<0.001),男性更多(84.8% vs 75.8%,p<0.001)。
- NPS相关患者自行离院比例更高(22.8% vs 15.1%),入住重症监护比例更低(3.6% vs 6.1%),住院时间更长(中位5.1小时(2.7-18.7)vs 4.7小时(2.5-9.2),p<0.001)。
- 涉及NPS的就诊中死亡发生率为0.5%,非NPS就诊中为0.4%。
证据类型、等级与局限
- 证据类型:多中心队列研究(基于Euro-DEN Plus数据库)。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Novel psychoactive substances (NPS) have been increasingly reported in the last 15-20 years. We aimed to describe presentations to the emergency department (ED) with acute recreational drug toxicity involving NPS.
METHODS: Data were extracted from the European Drug Emergencies Network (Euro-DEN) Plus database for all presentations to ED (36 EDs in 24 European countries) with acute toxicity between January 2014 and December 2019. Patient demographics, agents involved, and clinical outcomes were described and the subgroup of presentations involving NPS was compared with the rest of the cohort.
RESULTS: Out of 43,633 Euro-DEN Plus presentations, 3304 (7.6%) involved at least one NPS. Agents were identified mainly based on self-report or clinical presentation, with analytical confirmation being performed only in 17.9% of NPS presentations. The proportion of NPS presentations varied by centre (0-48.8%). For centres where data were available for all 6 years, NPS-related presentations peaked in 2015 (11.9%). In 2014, 78.4% of NPS agents reported were cathinones, while only 3.4% were synthetic cannabinoids (SCs); conversely, in 2019 only 11.6% of NPS agents reported were cathinones, while 72.2% were SCs. NPS-related presentations involved younger patients (median 30 (23-37) vs. 32 (25-40) years, p < 0.001) and more males (84.8 vs. 75.8%, p < 0.001) compared with the rest of the cohort. Patients presenting to ED after using NPS were more likely to self-discharge (22.8 vs. 15.1%), less likely to be admitted to critical care (3.6 vs. 6.1%) but had a longer length of stay in hospital (median 5.1 (2.7-18.7) vs. 4.7 (2.5-9.2) h, p < 0.001). Death occurred in 0.5% of all presentations involving NPS and in 0.4% of non-NPS presentations.
CONCLUSIONS: This large multicentre series of NPS presentations to European EDs showed marked geographical variation and changes over time in the proportion of presentations to ED involving NPS, as well as the proportion of NPS subgroups.
参考来源
- Crulli B, Dines AM, Blanco G, et al. Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014-2019. Clin Toxicol (Phila). 2022. PMID: 36322684. doi:10.1080/15563650.2022.2137524
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。